Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.
Explore these studies to deepen your understanding of the subject.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
J. Cortés, S. A. Hurvitz, et al.
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
N. Harbeck, E. Ciruelos, et al.
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
S. Peters, S. M. Gadgeel, et al.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
